The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC)

Inclusion Criteria: older than 18 years old and younger than 75 years; ECOG PS≤1; proven hepatocellularcarcinoma according patological examination or EASL/AASLD diagnostic criteria; not previoustreated for tumor; unresectable; the lab test could meet: neutrophil count≥2.0×109/L;hemoglobin≥100g/L; platelet count≥75×109/L; serum albumin≥35g/L; total bilirubin<2-timesupper limit of normal; ALT<3-times upper limit of normal; AST<3-times upper limit ofnormal; serum creatine<1.5-times upper limit of normal; PT≤upper limit of normal plus 4seconds; INR≤2.2; sign up consent

Exclusion Criteria: cannot tolerate TAI or surgery; known history of other malignancy; be allergic to relateddrugs; underwent organ transplantation before; be treated before (interferon included);known history of HIV infection; known history of drug or alcohol abuse; have GI hemorrhageor cardiac/brain vascular events within 30 days; pregnancy